• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

表皮生长因子受体酪氨酸激酶抑制剂用于接受血液透析的非小细胞肺癌患者的研究综述。

Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis.

作者信息

Lan Chou-Chin, Hsieh Po-Chun, Huang Chun-Yao, Yang Mei-Chen, Su Wen-Lin, Wu Chih-Wei, Wu Yao-Kuang

机构信息

Division of Pulmonary Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.

Department of Chinese Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.

出版信息

World J Clin Cases. 2022 Jul 6;10(19):6360-6369. doi: 10.12998/wjcc.v10.i19.6360.

DOI:10.12998/wjcc.v10.i19.6360
PMID:35979322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9294878/
Abstract

Non-small-cell lung cancer (NSCLC) causes significant mortality worldwide. Patients with chronic renal failure have an increased risk of developing lung cancer. NSCLC Patients with chronic renal failure undergoing hemodialysis (HD) often exhibit poor performance, and chemotherapy is generally contraindicated. Oral epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are effective treatment agents for NSCLC patients. However, the benefits and adverse effects of EGFR-TKIs in NSCLC undergoing HD are known. There are no clinical studies on the effects of EGFR-TKIs on NSCLC patients undergoing HD. We reviewed all previous case reports about EGFR-TKIs in NSCLC patients undergoing HD. It is difficult to design studies about the effects of EGFR-TKIs in patients undergoing HD, and this review is quite important. EGFR-TKIs are well tolerated in patients undergoing HD. The main routes of elimination of EGFR-TKIs are metabolism the liver, and renal elimination is minor. The recommended doses and pharmacokinetics of these EGFR-TKIs for patients undergoing HD are similar to those for patients with normal renal function. The plasma protein binding of EGFR-TKIs is very high, and it is not necessary to adjust the dose after HD. In conclusion, EGFR-TKIs are effective and well tolerated in patients undergoing HD.

摘要

非小细胞肺癌（NSCLC）在全球范围内导致了显著的死亡率。慢性肾衰竭患者患肺癌的风险增加。接受血液透析（HD）的NSCLC合并慢性肾衰竭患者通常表现较差，化疗一般为禁忌。口服表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKIs）是NSCLC患者的有效治疗药物。然而，EGFR-TKIs在接受HD的NSCLC患者中的获益和不良反应尚不清楚。目前尚无关于EGFR-TKIs对接受HD的NSCLC患者影响的临床研究。我们回顾了既往所有关于接受HD的NSCLC患者使用EGFR-TKIs的病例报告。设计关于EGFR-TKIs对接受HD患者影响的研究很困难，因此本综述相当重要。接受HD的患者对EGFR-TKIs耐受性良好。EGFR-TKIs的主要消除途径是肝脏代谢，肾脏消除作用较小。这些EGFR-TKIs用于接受HD患者的推荐剂量和药代动力学与肾功能正常的患者相似。EGFR-TKIs的血浆蛋白结合率非常高，血液透析后无需调整剂量。总之，EGFR-TKIs在接受HD的患者中有效且耐受性良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/5141e18f6903/WJCC-10-6360-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/dbb1a4f0c718/WJCC-10-6360-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/f73e6aec0c31/WJCC-10-6360-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/3701bbf289f1/WJCC-10-6360-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/046e5f500e4c/WJCC-10-6360-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/5141e18f6903/WJCC-10-6360-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/dbb1a4f0c718/WJCC-10-6360-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/f73e6aec0c31/WJCC-10-6360-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/3701bbf289f1/WJCC-10-6360-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/046e5f500e4c/WJCC-10-6360-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/693b/9294878/5141e18f6903/WJCC-10-6360-g005.jpg

相似文献

1
Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis.表皮生长因子受体酪氨酸激酶抑制剂用于接受血液透析的非小细胞肺癌患者的研究综述。
World J Clin Cases. 2022 Jul 6;10(19):6360-6369. doi: 10.12998/wjcc.v10.i19.6360.
2
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
3
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.表皮生长因子受体酪氨酸激酶抑制剂作为非小细胞肺癌的初始治疗：重点关注表皮生长因子受体突变检测和突变阳性患者。
Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.
4
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.表皮生长因子受体抑制剂作为表皮生长因子受体突变的可切除非小细胞肺癌的辅助治疗。
Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2.
5
Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.胰岛素样生长因子1受体（IGF-1R）的表达预示着携带激活型表皮生长因子受体（EGFR）突变的非小细胞肺癌患者对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂反应不佳。
Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.
6
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?我们能否确定表皮生长因子受体酪氨酸激酶抑制剂治疗表皮生长因子受体突变的非小细胞肺癌的最佳用药顺序？
Curr Opin Oncol. 2017 Mar;29(2):89-96. doi: 10.1097/CCO.0000000000000350.
7
[Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].用于治疗非小细胞肺癌软脑膜转移患者的表皮生长因子酪氨酸激酶抑制剂
Zhonghua Zhong Liu Za Zhi. 2016 Dec 23;38(12):920-924. doi: 10.3760/cma.j.issn.0253-3766.2016.12.008.
8
Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.表皮生长因子受体-酪氨酸激酶抑制剂在表皮生长因子受体突变阳性非小细胞肺癌患者中枢神经系统转移管理中的作用
Indian J Cancer. 2017 Dec;54(Supplement):S37-S44. doi: 10.4103/ijc.IJC_532_17.
9
Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.临床参数和全身炎症状态对表皮生长因子受体突变的非小细胞肺癌患者再次使用表皮生长因子受体酪氨酸激酶抑制剂的影响。
BMC Cancer. 2016 Nov 8;16(1):868. doi: 10.1186/s12885-016-2917-6.
10
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.表皮生长因子受体酪氨酸激酶抑制剂治疗前后表皮生长因子受体突变的非小细胞肺癌中的肿瘤免疫微环境：一篇叙述性综述
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.

引用本文的文献

1
Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy.代表性小分子表皮生长因子受体抑制剂的合成路线及其在癌症治疗中的临床应用。
Molecules. 2024 Mar 23;29(7):1448. doi: 10.3390/molecules29071448.
2
A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5-]quinoxaline derivatives hybrid with a sulfonamide moiety.一类具有抗增殖活性和凋亡诱导作用的新型化合物，对一种新型的带有磺酰胺基团的1,3 - 二硫杂环戊烯并[4,5 - ]喹喔啉衍生物进行分子对接研究。
RSC Adv. 2023 Apr 24;13(18):12589-12608. doi: 10.1039/d3ra01635h. eCollection 2023 Apr 17.

本文引用的文献

1
EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - A cost-effectiveness analysis.在香港，使用埃克替尼、厄洛替尼和吉非替尼进行表皮生长因子受体突变指导的晚期非小细胞肺癌的成本效益分析。
PLoS One. 2021 Mar 1;16(3):e0247860. doi: 10.1371/journal.pone.0247860. eCollection 2021.
2
Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring mutations.阿法替尼联合贝伐单抗治疗携带特定突变的晚期非鳞状非小细胞肺癌患者的I期研究
Transl Lung Cancer Res. 2021 Jan;10(1):183-192. doi: 10.21037/tlcr-20-824.
3
Mutation profile of non-small cell lung cancer revealed by next generation sequencing.
下一代测序揭示的非小细胞肺癌突变特征。
Respir Res. 2021 Jan 6;22(1):3. doi: 10.1186/s12931-020-01608-5.
4
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.阿法替尼用于初治的局部晚期或转移性表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者：一项3b期研究的中期分析
Lung Cancer. 2021 Feb;152:127-134. doi: 10.1016/j.lungcan.2020.12.011. Epub 2020 Dec 17.
5
The efficacy and safety of osimertinib in treating nonsmall cell lung cancer: A PRISMA-compliant systematic review and meta-analysis.奥希替尼治疗非小细胞肺癌的疗效与安全性：一项遵循PRISMA标准的系统评价和荟萃分析。
Medicine (Baltimore). 2020 Aug 21;99(34):e21826. doi: 10.1097/MD.0000000000021826.
6
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.非小细胞肺癌患者厄洛替尼的群体药代动力学：在老年患者中应用于个体化给药方案。
Clin Ther. 2020 Jul;42(7):1302-1316. doi: 10.1016/j.clinthera.2020.05.008. Epub 2020 Jul 4.
7
Albuminuria, Kidney Function, and Cancer Risk in the Community.社区人群中的白蛋白尿、肾功能与癌症风险。
Am J Epidemiol. 2020 Sep 1;189(9):942-950. doi: 10.1093/aje/kwaa043.
8
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.奥希替尼治疗未经治、-突变型晚期 NSCLC 的总生存期。
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
9
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.非小细胞肺癌中罕见的表皮生长因子受体（EGFR）突变。
Semin Cancer Biol. 2020 Apr;61:167-179. doi: 10.1016/j.semcancer.2019.09.015. Epub 2019 Sep 25.
10
Osimertinib in a patient with non-small cell lung cancer and renal failure undergoing hemodialysis: a case report.奥希替尼治疗接受血液透析的非小细胞肺癌合并肾衰竭患者 1 例报告
Invest New Drugs. 2020 Aug;38(4):1192-1195. doi: 10.1007/s10637-019-00851-y. Epub 2019 Sep 5.